Recro Pharma (REPH) PT Raised to $14 at Piper Jaffray
Tweet
Share
E-mailGet Alerts REPH Hot Sheet
Price: $2.09 --0%
Rating Summary:
10 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Rating Summary:
10 Buy, 1 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 7 | Down: 12 | New: 19
Join SI Premium – FREE
Piper Jaffray analyst David Amsellem raised the price target on Recro Pharma (NASDAQ: REPH) to $14.00 (from $11.00) while maintaining a Overweight rating.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Enhanced Group Inc. (ENHA) PT Lowered to $5 at Canaccord
- ADC Therapeutics (ADCT) PT Lowered to $5 at Guggenheim
- American Integrity Insurance Group (AII) PT Raised to $29 at Keefe, Bruyette & Woods
Create E-mail Alert Related Categories
Analyst PT ChangeRelated Entities
Piper JaffraySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
